Pan-Cancer Analysis Identified CD93 as a Valuable Biomarker for Predicting Patient Prognosis and Immunotherapy Response

Wen Tong, Guangyu Wang, Liuyang Zhu, Yi Bai, Zirong Liu, Long Yang, Hao Wu, Tao Cui, Yamin Zhang

Open source

DOI
10.3389/fmolb.2021.793445
Published
2022-02-21
Container
Frontiers in Molecular Biosciences
Publisher
Frontiers Media SA
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fmolb.2021.793445,
  title = {Pan-Cancer Analysis Identified CD93 as a Valuable Biomarker for Predicting Patient Prognosis and Immunotherapy Response},
  author = {Wen Tong and Guangyu Wang and Liuyang Zhu and Yi Bai and Zirong Liu and Long Yang and Hao Wu and Tao Cui and Yamin Zhang},
  year = {2022},
  journal = {Frontiers in Molecular Biosciences},
  doi = {10.3389/fmolb.2021.793445},
  url = {https://doi.org/10.3389/fmolb.2021.793445}
}

RIS

TY  - JOUR
TI  - Pan-Cancer Analysis Identified CD93 as a Valuable Biomarker for Predicting Patient Prognosis and Immunotherapy Response
AU  - Wen Tong
AU  - Guangyu Wang
AU  - Liuyang Zhu
AU  - Yi Bai
AU  - Zirong Liu
AU  - Long Yang
AU  - Hao Wu
AU  - Tao Cui
AU  - Yamin Zhang
PY  - 2022
JO  - Frontiers in Molecular Biosciences
DO  - 10.3389/fmolb.2021.793445
UR  - https://doi.org/10.3389/fmolb.2021.793445
ER  - 

APA

Tong, W., Wang, G., Zhu, L., Bai, Y., Liu, Z., Yang, L., Wu, H., Cui, T., & Zhang, Y. (2022). Pan-Cancer Analysis Identified CD93 as a Valuable Biomarker for Predicting Patient Prognosis and Immunotherapy Response. Frontiers in Molecular Biosciences. https://doi.org/10.3389/fmolb.2021.793445

Source records